⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875830 | 0.81 | — | — | |
| SCHEMBL8087786 | 0.78 | — | — | |
| SCHEMBL8087784 | 0.78 | — | — | |
| SCHEMBL2243 | 0.71 | — | — | |
| SCHEMBL8089335 | 0.69 | — | — | |
| SCHEMBL102446 | 0.67 | — | — | |
| SCHEMBL10840770 | 0.62 | — | — | |
| SCHEMBL10840182 | 0.62 | — | — | |
| SCHEMBL10840180 | 0.62 | — | — | |
| SCHEMBL10840778 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 18924 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | claimed |
| US-20240207300-A1 | COMBINATION THERAPIES INCLUDING MYT1 INHIBITORS | SINAI HEALTH SYSTEM (CA) | 2024-06-27 | — | — | US | claimed |
| WO-2024138018-A1 | TREATMENT OF GEMIN5-MEDIATED DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-06-27 | — | — | WO | claimed |
| CN-118203585-A | Pharmaceutical use of ENPP1 inhibitors | 上海翊石医药科技有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-118201933-A | Tri-fused ring compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-118201916-A | Piperazinylsulfonylaryl compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | claimed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | claimed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118084864-A | PRMT4 inhibitor, and pharmaceutical composition, pharmaceutical preparation and application thereof | 北京福元医药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | claimed |
| US-4287338-A | Sulfooxy-pyrimidinium, -pyridinium, and -triazinium hydroxide inner salts | THE UPJOHN COMPANY (US) | 1981-09-01 | — | — | US | claimed |
| US-4276417-A | TREATMENT OF VASCULAR-CONDITION HYPERTENSION | HOFFMANN-LA ROCHE INC. (US) | 1981-06-30 | — | — | US | claimed |
| US-4268669-A | 9-Deoxy-9-methylene-5,6-didehydro-PGF1 amides | THE UPJOHN COMPANY (US) | 1981-05-19 | — | — | US | claimed |
| US-4252957-A | GALLSTONE SOLVENTS | PFIZER INC. (US) | 1981-02-24 | — | — | US | claimed |
| EP-0007643-A1 | Oxadiazolotriazine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-02-06 | — | — | EP | claimed |
| US-4176119-A | OXADIAZOLOPYRIMIDINE DERIVATIVES USEFUL AS VASODILATORS OR HYPOTENSIVE AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1979-11-27 | — | — | US | claimed |
| EP-0004187-A1 | Heterocyclylcarbonyl derivatives of urea and their use as agents for dissolution of gallstones | PFIZER INC. (US) | 1979-09-19 | — | — | EP | claimed |
| US-4163784-A | ACYLUREA DERIVATIVES | PFIZER INC. (US) | 1979-08-07 | — | — | US | claimed |
| US-4150131-A | Substituted oxadiazolopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1979-04-17 | — | — | US | claimed |
| US-4113867-A | ANTHELMINTICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1978-09-12 | — | — | US | claimed |